Promius Pharma LLC, an affiliate of Dr. Reddy’s Laboratories, and Valeant Pharmaceuticals International Inc. April 1 announced that they have signed a collaboration agreement for Cloderm (clocortolone pivalate 0.1 percent) cream.
Cloderm cream is a topical steroid indicated for relieving the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, the companies said.
Under the agreement, Promius Pharma will make an up-front payment and pay future royalties in exchange for the right to manufacture, distribute, and market Cloderm in the United States, effective immediately. The financial terms and conditions have not been disclosed.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.